Table 1.
Baseline clinical characteristics of patients with atrial fibrillation (AF) as compared to the control group
| AF (41) n (%) | Controls (41) n (%) | P value | |
|---|---|---|---|
| Mean age (years) |
64.5 ± 4.0 |
61.7 ± 2.4 |
0.12 |
| Sex (M/F) |
29/12 |
13/28 |
<0.01 |
| BMI (Kg/m2) |
32.5 ± 2.3 |
25.8 ± 1.6 |
<0.01 |
|
Comorbid conditions: | |||
| HTN |
30 (73.2) |
16 (39) |
<0.01 |
| CAD |
14 (34.1) |
4 (9.7) |
<0.01 |
| Systolic HF |
13 (31.7) |
0 |
<0.01 |
| CVA |
1 (2.4) |
0 |
1.0 |
| DM |
11 (26.8) |
4 (9.7) |
0.08 |
| Dyslipidemia |
24 (58.5) |
9 (21.9) |
<0.01 |
|
Medications: | |||
| Statins |
22 (53.6) |
6 (14.6) |
<0.01 |
| Beta blockers |
27 (65.8) |
9 (21.9) |
<0.01 |
| ACE-i/ARB |
24 (58.5) |
8 (19.5) |
<0.01 |
| CCB |
17 (41.5) |
5 (12.2) |
<0.01 |
| Digoxin |
4 (9.7) |
0 |
0.11 |
| Diuretics |
21 (51.2) |
5 (12.2) |
<0.01 |
| ASA |
30 (73.2) |
5 (12.2) |
<0.01 |
| Clopidogrel |
2 (4.8) |
0 |
0.49 |
| Warfarin |
28 (68.3) |
3 (7.3) |
<0.01 |
| Heparin |
4 (9.7) |
0 |
0.11 |
| Amiodarone |
8 (19.5) |
0 |
<0.01 |
| Sotalol |
5 (12.2) |
0 |
0.05 |
| Other anti-arrhythmics | 4 (9.7) | 0 | 0.11 |
BMI – Body Mass Index, HTN – Hypertension, CAD – Coronary artery disease, HF- Heart failure, DM – Diabetes Mellitus, CVA – Cerebrovascular accident, ACE-i/ARB – Angiotensinogen converting enzyme inhibitors/Angiotensin receptor blockers, CCB – Calcium channel blockers, ASA - Aspirin.